Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Covid-19 Cases, Hospitalizations and Deaths After Vaccination: A Cohort Event Monitoring Study, Islamic Republic of Iran; [Cas, Hospitalisations Et Deces Lies a La Covid-19 Apres La Vaccination: Etude De Cohorte Portant Sur La Surveillance Des Evenements En Republique Islamique D'iran]; [Casos, Hospitalizaciones Y Muertes Por La Covid-19 Tras La Vacunacion: Un Estudio De Cohortes Sobre El Seguimiento De Eventos En La Republica Islamica De Iran] Publisher Pubmed



Hosseinzadeh A1 ; Sahabnegah S2 ; Nili S3 ; Aliyari R4 ; Goli S1 ; Fereidouni M5 ; Alami A6 ; Shati M7 ; Ahmadnezhad E8 ; Mehravaran S9 ; Fateh M10 ; Khajeha H4 ; Emamian Z11 ; Behmanesh E11 Show All Authors
Authors
  1. Hosseinzadeh A1
  2. Sahabnegah S2
  3. Nili S3
  4. Aliyari R4
  5. Goli S1
  6. Fereidouni M5
  7. Alami A6
  8. Shati M7
  9. Ahmadnezhad E8
  10. Mehravaran S9
  11. Fateh M10
  12. Khajeha H4
  13. Emamian Z11
  14. Behmanesh E11
  15. Mahdavi S1
  16. Enayatrad M12
  17. Shahrbabaki PM13
  18. Ansarimoghaddam A14
  19. Heidarzadeh A15
  20. Shahrakisanavi F14
  21. Shahri SMH16
  22. Dehghan M13
  23. Moridani MA17
  24. Sheibani H18
  25. Abbaszadeh M18
  26. Jafari R19
  27. Valikhani M18
  28. Binesh E18
  29. Vahedi H18
  30. Chaman R1
  31. Khodashahi R20
  32. Amini M21
  33. Azad FJ22
  34. Rezaeitalab F2
  35. Jamehdar SA23
  36. Eshraghi A24
  37. Sharifi H25
  38. Bajgani SMH26
  39. Mahdavi A27
  40. Jafarzadeh A28
  41. Farokhnia M29
  42. Ebrahimi S30
  43. Pardakhti A31
  44. Ghaderi E32
  45. Soltani H33
  46. Jadidoleslami S34
  47. Arianejad A34
  48. Gavili H34
  49. Moradveisi B35
  50. Motamedi D36
  51. Zare H5
  52. Kazemi T37
  53. Emamian MH4

Source: Bulletin of the World Health Organization Published:2022


Abstract

Objective To investigate the incidence of coronavirus disease 2019 (COVID-19) cases, hospitalizations and deaths in Iranians vaccinated with either AZD1222 Vaxzevria, CovIran® vaccine, SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) or Sputnik V. Methods We enrolled individuals 18 years or older receiving their first COVID-19 vaccine dose between April 2021 and January 2022 in seven Iranian cities. Participants completed weekly follow-up surveys for 17 weeks (25 weeks for AZD1222) to report their COVID-19 status and hospitalization. We used Cox regression models to assess risk factors for contracting COVID-19, hospitalization and death. Findings Of 89 783 participants enrolled, incidence rates per 1 000 000 person-days were: 528.2 (95% confidence interval, CI: 514.0–542.7) for contracting COVID-19; 55.8 (95% CI: 51.4–60.5) for hospitalization; and 4.1 (95% CI: 3.0–5.5) for death. Compared with SARS-CoV-2 Vaccine (Vero Cell), hazard ratios (HR) for contracting COVID-19 were: 0.70 (95% CI: 0.61−0.80) with AZD1222; 0.73 (95% CI: 0.62–0.86) with Sputnik V; and 0.73 (95% CI: 0.63–0.86) with CovIran®. For hospitalization and death, all vaccines provided similar protection 14 days after the second dose. History of COVID-19 protected against contracting COVID-19 again (HR: 0.76; 95% CI: 0.69–0.84). Diabetes and respiratory, cardiac and renal disease were associated with higher risks of contracting COVID-19 after vaccination. Conclusion The rates of contracting COVID-19 after vaccination were relatively high. SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions. © 2022, World Health Organization. All rights reserved.
Other Related Docs